NEW YORK, February 9, 2017 /PRNewswire/ --
On Wednesday, February 08, 2017, the NASDAQComposite ended the trading session at 5,682.45, up 0.15%; the Dow Jones Industrial Average edged 0.18% lower, to finish at 20,054.34; and the S&P 500 closed at 2,294.67, advancing slightly by 0.07%. Gains were broad based as six out of nine sectors
On Wednesday, shares in Irvine, California headquartered Aerie Pharmaceuticals Inc. ended the session 4.67% higher at $44.80 with a total volume of 367,189 shares traded. Aerie Pharma's shares have surged 12.56% in the last one month and 31.57% in the previous three months. Furthermore, the stock has rallied 224.64% in the past one year. The stock is trading 11.80% above its 50-day moving average and 59.12% above its 200-day moving average. Moreover, shares of the Company, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have a Relative Strength Index (RSI) of 63.78. Sign up and read the free research report on AERI at:
On Wednesday, shares in Cambridge, the UK-based GW Pharmaceuticals PLC recorded a trading volume of 675,550 shares, which was above their three months average volume of 469,750 shares. The stock ended the day 4.01% higher at $128.90. GW Pharma's stock has gained 7.40% in the last one month and 8.16% in the previous three months. Furthermore, the stock has rallied 216.16% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 10.52% and 24.17%, respectively. Furthermore, shares of GW Pharma have an RSI of 69.52. The complimentary research report on GWPH can be downloaded at:
San Diego, California headquartered Retrophin Inc.'s stock finished Wednesday's session 0.64% higher at $20.44 with a total volume of 224,525 shares traded. Over the last one month and the previous three months, Retrophin's shares have advanced 4.02% and 11.57%, respectively. Furthermore, the stock has surged 48.76% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 3.64% and 7.94%, respectively. Shares of Retrophin, which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, have an RSI of 57.46. Register for free on Stock-Callers.com and access the latest report on RTRX at:
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s stock declined 1.52%, to close the day at $9.70. The stock recorded a trading volume of 174,303 shares. SciClone Pharma's shares have gained 8.38% in the previous three months and 20.20% in the past one year. The Company's shares are trading 6.10% and 12.80% below its 50-day and 200-day moving averages, respectively. Shares of the Company, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, are trading at a PE ratio of 12.95. Additionally, the stock has an RSI of 32.40. Get free access to your research report on SCLN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All